Literature DB >> 27993214

Predictors of residual disease after unplanned excision of soft tissue sarcomas.

Alicia A Gingrich1, Alexandra Elias1, Chia-Yuan Michael Lee2, Yves-Paul N Nakache1, Chin-Shang Li3, Dhruvil R Shah1, Robert D Boutin4, Robert J Canter5.   

Abstract

BACKGROUND: Unplanned excision of soft tissue sarcomas (STS) is an important quality of care issue given the morbidity related to tumor bed excision. Since not all patients harbor residual disease at the time of reexcision, we sought to determine predictors of residual STS following unplanned excision.
METHODS: We identified 76 patients from a prospective database (January 1, 2008-September 30, 2014) who received a diagnosis of primary STS following unplanned excision on the trunk or extremities. We used univariable and multivariable analyses to evaluate predictors of residual STS as the primary endpoint. We calculated the sensitivity, specificity, and accuracy of interval magnetic resonance imaging (MRI) to predict residual sarcoma at reexcision.
RESULTS: Mean age was 52 y, and 63.2% were male. 50% had fragmented unplanned excision. Among patients undergoing reexcision, residual STS was identified in 70%. On univariable analysis, MRI showing gross disease and fragmented excision were significant predictors of residual STS (odds ratio, 10.59; 95% CI, 2.14-52.49; P = 0.004 and odds ratio, 3.61; 95% CI, 1.09-11.94; P = 0.035, respectively). On multivariable analysis, tumor size predicted distant recurrence and overall survival. When we combined equivocal and positive MRI, the sensitivity and specificity of MRI for predicting residual STS were 86.7% (95% CI, 73.2%-95.0%) and 57.9% (95% CI, 33.5%-79.8%), with an overall accuracy of 78.1% (95% CI, 66.0%-87.5%).
CONCLUSIONS: About 70% of patients undergoing repeat excision after unplanned excision of STS harbor residual sarcoma. Although interval MRI and fragmented excision appear to be the most significant predictors of residual STS, the accuracy of MRI remains modest, especially given the incidence of equivocal MRI.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRI; Residual disease; Soft tissue sarcoma; Unplanned excision

Mesh:

Year:  2016        PMID: 27993214      PMCID: PMC5180207          DOI: 10.1016/j.jss.2016.08.096

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  22 in total

1.  MR imaging in the assessment of residual tumour following inadequate primary excision of soft tissue sarcomas.

Authors:  A M Davies; A Mehr; S Parsonage; N Evans; R J Grimer; P B Pynsent
Journal:  Eur Radiol       Date:  2003-10-14       Impact factor: 5.315

2.  Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients needing re-excision after local resection.

Authors:  J R Goodlad; C D Fletcher; M A Smith
Journal:  J Bone Joint Surg Br       Date:  1996-07

3.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

Authors:  P W Pisters; D H Leung; J Woodruff; W Shi; M F Brennan
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  Models for complex contingency tables and polychotomous dosage response curves.

Authors:  N Mantel
Journal:  Biometrics       Date:  1966-03       Impact factor: 2.571

5.  Unplanned excision of soft tissue sarcoma results in increased rates of local recurrence despite full further oncological treatment.

Authors:  Y A Qureshi; J R Huddy; J D Miller; D C Strauss; J M Thomas; A J Hayes
Journal:  Ann Surg Oncol       Date:  2011-07-27       Impact factor: 5.344

Review 6.  The evolving classification of soft tissue tumours: an update based on the new WHO classification.

Authors:  C D M Fletcher
Journal:  Histopathology       Date:  2006-01       Impact factor: 5.087

7.  Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.

Authors:  Robert J Canter; Dariusz Borys; Abimbola Olusanya; Chin-Shang Li; Li-Yuan Lee; Robert D Boutin; Scott D Christensen; Robert M Tamurian; Arta M Monjazeb
Journal:  Ann Surg Oncol       Date:  2014-02-20       Impact factor: 5.344

8.  Residual disease following unplanned excision of soft-tissue sarcoma of an extremity.

Authors:  S Noria; A Davis; R Kandel; J Levesque; B O'Sullivan; J Wunder; R Bell
Journal:  J Bone Joint Surg Am       Date:  1996-05       Impact factor: 5.284

9.  Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma.

Authors:  Robert J Canter; Steve R Martinez; Robert M Tamurian; Maaya Wilton; Chin-Shang Li; Janice Ryu; Walter Mak; Wayne L Monsky; Dariusz Borys
Journal:  Ann Surg Oncol       Date:  2010-06-17       Impact factor: 5.344

10.  The effect of an unplanned excision of a soft-tissue sarcoma on prognosis.

Authors:  C R Chandrasekar; H Wafa; R J Grimer; S R Carter; R M Tillman; A Abudu
Journal:  J Bone Joint Surg Br       Date:  2008-02
View more
  8 in total

1.  Unplanned excision of soft tissue sarcoma: does it impact the accuracy of intra-operative pathologic assessment at time of re-excision?

Authors:  Shai S Shemesh; Erika L Garbrecht; Tal Frenkel Rutenberg; Sheila A Conway; Andrew E Rosenberg; Juan Pretell-Mazzini
Journal:  Int Orthop       Date:  2021-08-20       Impact factor: 3.075

2.  Standard Treatment Remains the Recommended Approach for Patients with Bone Sarcoma Who Underwent Unplanned Surgery: Report from the Japanese Musculoskeletal Oncology Group.

Authors:  Tomoki Nakamura; Jun Sugaya; Norifumi Naka; Hiroshi Kobayashi; Tomotake Okuma; Toshiyuki Kunisada; Kunihiro Asanuma; Hedetatsu Outani; Shunji Nishimura; Hiroyuki Kawashima; Toru Akiyama; Taketoshi Yasuda; Shinji Miwa; Akihiro Sudo; Takafumi Ueda
Journal:  Cancer Manag Res       Date:  2020-10-12       Impact factor: 3.989

3.  Clinical Outcomes and Prognostic Factors in Soft Tissue Sarcoma Patients After Unplanned Excision.

Authors:  Toshiyuki Takemori; Teruya Kawamoto; Hitomi Hara; Naomasa Fukase; Shuichi Fujiwara; Kazumichi Kitayama; Shunsuke Yahiro; Tomohiro Miyamoto; Yutaka Mifune; Yuichi Hoshino; Kenichiro Kakutani; Tomoyuki Matsumoto; Takehiko Matsushita; Takahiro Niikura; Ryosuke Kuroda; Toshihiro Akisue
Journal:  Cancer Manag Res       Date:  2022-05-25       Impact factor: 3.602

4.  Clinical and Radiologic Features Together Better Predict Lung Nodule Malignancy in Patients with Soft-Tissue Sarcoma.

Authors:  Cecilia Tetta; Antonio Giugliano; Laura Tonetti; Michele Rocca; Alessandra Longhi; Francesco Londero; Gianmarco Parise; Orlando Parise; Linda Renata Micali; Mark La Meir; Jos G Maessen; Sandro Gelsomino
Journal:  J Clin Med       Date:  2020-04-23       Impact factor: 4.241

5.  Musculoskeletal Soft-Tissue Sarcoma: Quality Assessment of Initial MRI Reports Shows Frequent Deviation from ESSR Guidelines.

Authors:  Sebastian Weiss; Alexander Korthaus; Nora Baumann; Jin Yamamura; Alexander S Spiro; Andreas M Lübke; Karl-Heinz Frosch; Carsten Schlickewei; Matthias Priemel
Journal:  Diagnostics (Basel)       Date:  2021-04-14

6.  The Impact of Unplanned Excision on the Outcomes of Patients With Soft Tissue Sarcoma of the Trunk and Extremity: A Propensity Score Matching Analysis.

Authors:  Yao Liang; Tian-Hui Guo; Bu-Shu Xu; Dong-Chun Hong; Hai-Bo Qiu; Zhi-Wei Zhou; Xing Zhang
Journal:  Front Oncol       Date:  2021-01-22       Impact factor: 6.244

Review 7.  Re-excision after unplanned excision of soft tissue sarcoma: A systematic review and metanalysis. The rationale of systematic re-excision.

Authors:  Federico Sacchetti; Andac Celasun Alsina; Riccardo Morganti; Matteo Innocenti; Lorenzo Andreani; Francesco Muratori; Guido Scoccianti; Francesca Totti; Domenico Andrea Campanacci; Rodolfo Capanna
Journal:  J Orthop       Date:  2021-05-14

8.  MRI after Whoops procedure: diagnostic value for residual sarcoma and predictive value for an incomplete second resection.

Authors:  Mohammed H A Alramdan; Ömer Kasalak; Lukas B Been; Albert J H Suurmeijer; Derya Yakar; Thomas C Kwee
Journal:  Skeletal Radiol       Date:  2021-04-26       Impact factor: 2.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.